8 completed, 2 unknown, 1 not yet recruiting. 7 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Corestemchemon, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse CE211NS21 - Neuromyelitis Optica Spectrum Disorder Relapse | Phase 1 | Not yet recruiting | Corestemchemon, Inc. | 6 | 2026-12-01 | 2026-05-19 |
| Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS Lenzumestrocel, Riluzole - Amyotrophic Lateral Sclerosis | Phase 1 | Completed | Corestemchemon, Inc. | 8 | 2022-11-09 | 2024-11-06 |
| Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS Lenzumestrocel, Riluzole, Placebo Comparator - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Corestemchemon, Inc. | 123 | 2021-02-24 | 2026-04-30 |
| Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) - Systemic Lupus Erythematosus | Phase 2 | Unknown | Hanyang University Seoul Hospital | 10 | 2019-09-26 | 2021-04-08 |
| Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101) Multiple System Atrophy | Completed | Corestemchemon, Inc. | 8 | 2018-08-28 | 2025-01-07 | |
| Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy CS10BR05 - Multiple System Atrophy | Phase 1 | Completed | Corestemchemon, Inc. | 9 | 2018-04-13 | 2024-10-18 |
| Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus Nephritis Lupus Nephritis | Completed | Corestemchemon, Inc. | 6 | 2017-11-29 | 2025-01-10 | |
| Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis allogenic bone marrow derived mesenchymal stem cells - Lupus Nephritis | Phase 1 | Completed | Corestemchemon, Inc. | 7 | 2017-05-30 | 2019-11-20 |
| Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS HYNRCS-Allo inj - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | Hanyang University Seoul Hospital | 6 | 2017-02-01 | 2019-05-16 |
| Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis HYNR-CS-Allo - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 1 | Completed | Hanyang University Seoul Hospital | 6 | 2012-12-01 | 2019-05-16 |
| Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis HYNR-CS inj, Control group - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Completed | Corestemchemon, Inc. | 72 | 2011-02-01 | 2022-03-17 |
Amyotrophic Lateral Sclerosis (5) · Lupus Erythematosus, Systemic (3) · Lupus Nephritis (3) · Motor Neuron Disease (3) · Central Nervous System Diseases (2) · Multiple System Atrophy (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2)
Riluzole (2) · Control Groups (1)
South Korea (10)
Seung Hyun Kim, MD, PhD (2) · Chan-Bum Choi, M.D.,Ph.D. (1) · Phil Hyu Lee, M.D. (1) · Phil Hyu Lee, MD (1) · Seung Hyun Kim, M.D., Ph.D (1) · Seung Hyun Kim, M.D., Ph.D. (1) · Seung Hyun Kim, M.D.,Ph.D. (1)